Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 95%
filed 2026-10-19
Item 5.07
This Item 5.07 filing discloses the results of Empery Digital's October 14, 2026 annual meeting of stockholders, including voting outcomes on three proposals: election of nine directors, approval/rejection of the 2025 Equity Incentive Plan, and ratification of MaloneBailey, LLP as independent auditors. The detailed vote tallies (For/Against/Withhold/Abstain) for each proposal are the core disclosure, making this a textbook shareholder_vote_results event. The material governance contest noted at the end (ATG's Section 225 action to sterilize votes and replace Ian Read with Gabriel Gliksberg) underscores the materiality of these voting outcomes to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-10-19
Item 5.03
Shareholders approved an Extraordinary General Meeting on October 13, 2026, voting to extend the business combination deadline to February 19, 2027, amend the trust agreement to permit monthly extensions, and adjourn the meeting. All three proposals passed with substantial majorities (6,745,828 for, 1,665,624 against).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-10-16
Item 5.07
On October 16, 2026, Archimedes Tech SPAC Partners II Co. shareholders voted to approve a material business combination with Forge Nano, Inc., with the Business Combination Proposal receiving 15,416,866 votes in favor versus 1,113,414 against, along with approval of related proposals including director elections, stock issuance, and organizational documents.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-30
Item 5.07
This Item 5.07 disclosure reports the results of AeroVironment's 2026 Annual Meeting of Stockholders held on September 24, 2026, including voting outcomes for three proposals: election of five directors, ratification of Deloitte & Touche LLP as independent auditors, and an advisory vote on named executive officer compensation. The filing presents vote tallies (For, Against, Abstain, Broker Non-Votes) for each matter, which is the core content of shareholder_vote_results disclosures.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-30
The 6-K discloses the results of an Extraordinary General Meeting held on September 30, 2026, reporting that all resolutions presented to shareholders were duly passed, with 40,433,365 shares represented out of 193,193,810 outstanding. This is a direct disclosure of shareholder vote results, matching the shareholder_vote_results event type. The materiality is high because EGM resolutions typically address significant corporate matters (governance, capital structure, or strategic decisions) that would affect investor assessment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-29
Item 5.07
FedEx held its annual stockholder meeting on September 28, 2026, with voting results on six proposals: election of eleven directors, advisory approval of named executive officer compensation, ratification of Ernst & Young LLP as independent auditor, and three stockholder proposals (all rejected).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-29
Item 5.07
TechPrecision Corporation held its Annual Meeting on September 29, 2026, with shareholders voting on four proposals: election of five directors, ratification of CBIZ CPAs P.C. as independent auditor, advisory approval of named executive officer compensation, and approval of an amended and restated 2016 Equity Incentive Plan increasing authorized shares by 750,000 and extending the plan's expiration to 2036.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-29
Item 5.07
Shareholders approved an Extension Amendment at an extraordinary general meeting on September 25, 2026, with 7,074,069 votes in favor and 57,456 against, extending the business combination deadline to March 29, 2027.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-29
Item 5.07
Shareholders approved dissolution and liquidation of the company under a Plan of Complete Liquidation and Dissolution, and advisory approval of executive compensation in connection with the liquidation, at a Special Meeting held on September 29, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-29
Item 5.07
Cadrenal Therapeutics held its 2026 Annual Meeting on September 24, 2026, with shareholders voting on five proposals: election of Class I director Quang X. Pham, ratification of WithumSmith+Brown as independent auditor, approval of Amendment No. 2 to the 2022 Successor Equity Incentive Plan (increasing share pool by 323,542 shares to 1,000,000 total), approval of warrant exercise issuance, and adjournment authority. The detailed voting results confirm shareholder approval of the equity plan amendment and dilutive warrant issuance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-29
The filing discloses Item 5.07 results from Citius Oncology's 2026 annual meeting of stockholders held on September 29, 2026, including election of three Class II directors (Dr. Eugene Holuka, Robert Smith, and Carol Webb) and ratification of Wolf & Company, P.C. as independent auditor, with specific vote tallies provided for each matter. This is a standard shareholder vote results disclosure that is material to investors as it reflects governance outcomes and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-29
Item 5.07
This is a clear disclosure of shareholder vote results from Byrna Technologies' 2026 Annual Meeting of Stockholders held on September 25, 2026. The filing reports voting outcomes for three proposals: election of eight directors, ratification of EisnerAmper LLP as independent auditors, and non-binding approval of executive compensation. The detailed vote tallies (votes for, against, abstained, and broker non-votes) for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-29
The 6-K discloses results of an extraordinary general meeting held on September 29, 2026, where shareholders approved multiple material proposals including a reverse share split at 1-for-150, an increase in authorized share capital, and amendments to the memorandum and articles of association. This is a classic shareholder vote results disclosure that would materially affect investor holdings and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-29
The filing discloses Item 5.07 results from Bone Biologics' Annual Meeting of stockholders held on September 28, 2026, including voting outcomes on six proposals: director elections (Stroever, Angle, Gagnon, Meikle), advisory compensation approval, auditor ratification (Weinberg & Company), warrant issuance authorization under Nasdaq Rule 5635(d), reverse stock split authorization (1-for-2 to 1-for-10), and meeting adjournment. All proposals passed. This is a material shareholder vote disclosure affecting investor understanding of governance and capital structure decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-29
The filing discloses results of a Special Meeting held on September 24, 2026, where stockholders voted on three proposals: (1) an Extension Proposal to extend the business combination deadline from September 28, 2026 to March 28, 2027; (2) a Trust Amendment Proposal to amend the Investment Management Trust Agreement; and (3) an Adjournment Proposal. All three proposals were approved with overwhelming support (3,437,439 votes FOR, 4,523 AGAINST, 2,500 ABSTAINED). Item 5.07 explicitly governs submission of matters to a vote of security holders, and the filing presents detailed voting tallies and outcomes. This is material to investors as it determines the company's continued existence as a SPAC and extends its timeline to complete a business combination.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-29
Item 5.07
The Company held its annual meeting of stockholders on September 29, 2026, and disclosed voting results for the election of seven directors and ratification of Deloitte & Touche as independent auditor, with detailed vote tallies for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-29
Item 5.07
This Item 5.07 disclosure reports the results of the Annual Meeting of Shareholders held on September 24, 2026, including voting outcomes on three proposals: election of directors (with detailed vote tallies for Class A and Class B shareholders), ratification of PricewaterhouseCoopers LLP as independent auditors, and an advisory vote on named executive officer compensation. The filing directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-29
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on September 24, 2026. The filing reports voting outcomes on five proposals: election of six directors, approval of an equity incentive plan amendment, advisory vote on executive compensation, ratification of auditors (BDO USA, P.C.), and adjournment authority. All proposals passed with majority support, making this a material governance event that affects investor understanding of board composition and capital allocation authority.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-09-29
Item 8.01
Shareholders approved an amendment to extend the Company's business combination deadline from December 17, 2027 to December 17, 2029 at an Extraordinary General Meeting held on September 4, 2026, with 10,625,000 votes in favor and no votes against. The approval was accompanied by significant shareholder redemptions of 1,801,349 shares for approximately $22.2 million.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-28
Item 5.07
This is a classic Item 5.07 disclosure reporting the final voting results from Conagra's Annual Meeting of Shareholders held on September 23, 2026. The filing presents results for four matters: election of eleven directors, advisory approval of named executive officer compensation ("Say-on-Pay"), ratification of KPMG LLP as independent auditor, and a shareholder proposal on blank-check preferred stock. All four votes passed with substantial majorities. This is a material governance event affecting investor understanding of board composition, executive compensation approval, and auditor ratification.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-28
The 6-K discloses the results of MakeMyTrip's annual shareholders' meeting held on September 28, 2026, stating that "all of the resolutions submitted to MakeMyTrip's shareholders at the above meeting were duly approved and passed." This is a direct disclosure of shareholder vote results, which is a material governance event that investors rely upon to understand the outcome of corporate actions put to a vote.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-28
Item 5.07
Korn Ferry held its 2026 Annual Meeting of Stockholders and disclosed final voting results for the election of nine directors, approval of executive compensation, approval of an amended and restated stock incentive plan increasing available shares by 1.4 million and extending the plan term to 2036, and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-28
The 6-K discloses the results of an Extraordinary General Meeting of Shareholders held on September 22, 2026, where shareholders voted on and approved a share consolidation resolution (40-for-1 consolidation). The filing presents voting tallies (67,997,978 votes for, 274,430 against, 7,322 abstain) representing 90.68% of exercisable votes, which is a direct disclosure of shareholder vote results under Item 5.07 equivalent. The share consolidation is a material capital structure change requiring shareholder approval.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 75%
filed 2026-09-28
The filing discloses the adjournment of an Extraordinary General Meeting of shareholders scheduled to vote on a proposed business combination with WISeSat.Space Corp. While technically an adjournment rather than vote results, this is a material shareholder meeting event under Item 8.01 that directly impacts the timing and conduct of a shareholder vote on a material M&A transaction. The meeting was reconvened on September 28, 2026 and adjourned again to September 29, 2026 without conducting business, which is a significant governance event affecting shareholder voting rights on the proposed business combination.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-28
Item 5.07
This Item 5.07 discloses the results of Lakewood-Amedex's 2026 Annual Meeting of Stockholders held on September 22, 2026, including voting outcomes on five proposals: election of four directors, amendment to increase authorized shares from 12.5M to 100M, authorization for a reverse stock split up to 1:20, amendment to the 2020 Equity Incentive Plan to increase shares to 400,000, and ratification of CBIZ CPAs P.C. as independent auditor. All proposals passed with substantial majorities. The authorization for a reverse stock split and increase in authorized shares are particularly material to investors assessing potential dilution and capital structure changes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-28
Item 5.07
This Item 5.07 disclosure reports the results of Friedman Industries' Annual Meeting of Shareholders held on September 22, 2026, including voting outcomes on director elections (all six nominees elected), a non-binding advisory vote on executive compensation (approved with 4,034,540 shares for), ratification of Baker Tilly US, LLP as independent auditor (approved with 5,946,451 shares for), and a failed amendment to the Articles of Incorporation regarding shareholder bylaw amendment rights (rejected with insufficient affirmative votes). The disclosure is material as it documents shareholder governance decisions and approval of executive compensation and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-28
Item 5.07
Stockholders voted at the Annual Meeting of Stockholders on three proposals: election of six directors, ratification of Grant Thornton, LLP as independent auditor, and approval of an amendment to the 2020 Long Term Incentive Plan increasing the share reserve by 1,500,000 shares. Detailed voting results for each proposal and director nominee were disclosed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-28
Item 5.07
This is a clear disclosure of shareholder voting results from ParkerVision's Annual Meeting of Shareholders held on September 25, 2026. The filing reports final voting tallies for two proposals: election of Class I and Class II directors (Jeffrey L. Parker and Anthony B. Bowers) and ratification of Frazier & Deeter, LLC as independent auditor. This is the quintessential Item 5.07 disclosure and is material to investors as it confirms governance outcomes and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-28
Item 5.07
This is a clear disclosure of shareholder vote results from a special meeting held on September 22, 2026. The filing reports voting outcomes on two proposals: (1) approval of a reverse stock split (1-for-5 to 1-for-20 ratio) with 114,398,602 votes for and (2) approval of adjournment with 114,344,814 votes for. Both proposals passed with overwhelming majorities (>98% approval). A reverse stock split is a material capital structure event that would affect all shareholders, making this disclosure material to investors.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 92%
filed 2026-09-28
The 6-K furnishes results of Coincheck Group's annual general meeting held September 25, 2026, disclosing shareholder votes on nine proposals including adoption of annual accounts, director appointments (including new director Shumpei Tatebayashi from KDDI Corporation), auditor reappointment, and authorizations for share issuance and repurchase. This is a classic shareholder_vote_results disclosure. The appointment of Tatebayashi and the resignation of Executive Chairperson Takashi Oyagi (disclosed separately on September 17, 2026) are material governance changes, making the vote results material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-28
Item 5.07
Anavex held its 2026 Annual Meeting on September 24, 2026, where shareholders voted on the election of six directors and ratification of Grant Thornton LLP as independent auditor. The Company's slate of director nominees defeated a contested slate of six PVG-nominated candidates, with detailed voting tallies certified by the Inspector of Elections.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-25
Item 5.07
This Item 5.07 disclosure reports the results of a special meeting of stockholders held on September 24, 2026, where shareholders voted on two proposals: approval of stock issuance upon conversion of 5.00% Senior Convertible Notes due 2033 (Proposal 1, which passed with 51,188,980 votes for vs. 5,175,849 against) and approval of adjournment if needed (Proposal 2). The filing directly states voting results with vote counts, meeting date, record date, and quorum information, which is the core content of Item 5.07 shareholder vote results disclosures. The approval of convertible note conversion is material to investors as it affects share dilution and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-25
Item 5.07
This is a clear disclosure of shareholder vote results under Item 5.07. The filing reports the outcomes of two proposals voted on at an extraordinary general meeting on September 23, 2026: an Authorized Share Capital Increase Proposal (rejected 75.4% against) and a Reverse Share Split Proposal (rejected 74.1% against). Both proposals failed to achieve majority approval. The rejection of these capital structure proposals is material to investors as it affects the Company's ability to execute planned financing or restructuring strategies.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 45%
filed 2026-09-25
Item 8.01
This disclosure announces a special meeting of stockholders scheduled for October 28, 2026, to vote on proposed amendments to preferred stock certificates of designations that would change dividend payment frequency from periodic to daily. While the filing is technically Item 8.01 (Other Events) rather than Item 5.07, the core event is a stockholder vote on material preferred stock terms. However, this is a pre-vote announcement rather than a results disclosure, creating ambiguity about whether to classify as shareholder_vote_results or operational_other.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-25
Item 5.07
This Item 5.07 filing discloses the results of a special shareholder meeting held on September 23, 2026, where shareholders voted to approve a Merger Agreement between MPCF and JHCPIF. The vote results (8,256,379.591 votes for, 0 against, 0 abstain) represent shareholder approval of a material acquisition/merger transaction. This is a classic shareholder_vote_results disclosure, and the underlying merger is material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-25
Item 5.07
Worthington Enterprises held its Annual Meeting on September 22, 2026, with shareholders voting on and approving three proposals: election of three directors (Chiappone, Southern, and Standridge), advisory approval of named executive officer compensation, and ratification of KPMG LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-25
Item 5.07
This Item 5.07 filing discloses the results of a special meeting of stockholders held on September 23, 2026, where shareholders voted on two proposals: (1) approval of a reverse stock split amendment at a ratio of 1-for-2 to 1-for-2,000, and (2) approval to adjourn the meeting if necessary. Both proposals were approved by stockholders with overwhelming majorities (707.9M votes for the reverse split vs. 1.5M against). A reverse stock split is a material capital structure event that affects all shareholders and is typically undertaken to address delisting risk or improve stock price perception.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-25
Item 5.07
Equitable Holdings held its Annual Meeting of Stockholders on September 23, 2026, with shareholders voting on three proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-25
The filing discloses Item 5.07 results from HeartCore Enterprises' 2026 annual meeting of stockholders held on September 25, 2026. The company reports voting results for two matters: (1) election of five directors (Sumitaka Yamamoto, Ferdinand Groenewald, Kimio Hosaka, Yoonji Lee, and Koji Sato), each receiving substantial "For" votes with minimal opposition, and (2) ratification of MaloneBailey, LLP as the independent registered public accounting firm for fiscal year 2026, with 839,950 votes in favor. This is a standard shareholder vote results disclosure material to investors' understanding of board composition and auditor selection.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-25
EX-99.2
Shareholders of Li Bang International approved six major proposals at the September 2026 Extraordinary General Meeting, including a massive increase in authorized Class A share capital from 15.75 million to 3.15 billion shares, a share capital reorganization reducing par value from $0.002 to $0.00001, adoption of an amended memorandum of association, and deregistration from the Cayman Islands with continuation into the British Virgin Islands.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-09-25
The filing discloses Item 5.07 results from a special stockholder meeting held on September 23, 2026, where shareholders voted on a proposal to amend the certificate of incorporation to reduce authorized shares of common stock from 681 million to 13.1 million and preferred stock from 10 million to 1 million. The proposal passed with 2,680,894 votes in favor versus 162,791 against, representing a material capital structure change requiring shareholder approval.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-09-25
The filing discloses Item 5.07 (Submission of Matters to a Vote of Security Holders), reporting that Co-Diagnostics held its Annual Meeting of Stockholders on September 3, 2026, but failed to achieve a quorum twice (September 3 and September 24), requiring adjournment to September 30, 2026. While no votes were actually cast due to lack of quorum, this is a material governance event affecting the company's ability to conduct shareholder business and elect directors or approve matters requiring stockholder approval.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-24
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Darden's Annual Meeting of Shareholders held on September 23, 2026. The filing presents certified voting results for four matters: election of 9 directors, advisory approval of executive compensation, ratification of KPMG LLP as independent auditor, and a shareholder proposal on director support review. All results are material to shareholders' understanding of governance and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-09-24
Item 5.07
Iridium Communications stockholders voted on September 24, 2026, to approve the Merger Agreement with Rocket Lab Corporation, with approximately 99.6% of votes cast in favor (85,862,105 for vs. 318,415 against) and 81.0% of outstanding shares entitled to vote represented. Stockholders also approved advisory compensation for golden parachute arrangements (74,461,703 for vs. 10,948,729 against).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-24
Item 5.07
AAR Corp held its Annual Meeting of stockholders on September 23, 2026, with shareholders voting on four proposals: election of Class III directors (Dietrich, Leduc, Pace), advisory approval of fiscal 2026 executive compensation, approval of the 2026 Stock Plan, and ratification of KPMG LLP as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-09-24
Item 8.01
The filing discloses results of the Annual Meeting of Stockholders held on August 3, 2026, reporting that Walter W. Buckley, III was elected as a Class I Director, while the election of Barbara J. Fouss was adjourned due to lack of quorum among preferred stockholders. This is a shareholder vote result disclosure under Item 8.01, though the outcome is incomplete and subject to further reconvening meetings scheduled for October 6, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-24
Item 5.07
AMC held its Annual Meeting of Stockholders and reported detailed voting results across nine proposals, including director elections, amendments to the Certificate of Incorporation, approval of the 2024 Equity Incentive Plan amendment (doubling the share pool from 25 million to 50 million shares), ratification of Ernst & Young as auditor, and advisory votes on executive compensation. Certain proposals including board declassification and stockholder rights amendments failed to pass.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-24
The 6-K discloses the results of Wise Group plc's Annual General Meeting held on 24 September 2026, including poll vote tallies for eight resolutions covering auditor appointment (PricewaterhouseCoopers LLP), director elections (David Bolling Wells, Emmanuel Thomassin, Terri Lynn Duhon, Hooi Ling Tan), auditor remuneration authorization, and share repurchase authorization. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and is material because it confirms governance outcomes including auditor selection and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-24
Item 5.07
Stockholders voted at the July 31, 2026 annual meeting on four matters: election of ten directors, advisory vote on named executive officer compensation, ratification of Grant Thornton LLP as auditor, and approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 1,000,000. All four proposals passed with substantial majorities.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-24
EX-99.1
This exhibit discloses the voting results from Legend Biotech's 2026 Annual General Meeting held on September 24, 2026, including shareholder approval of director re-elections, auditor ratification, and amendment to the 2020 Restricted Shares Plan to increase shares reserved for issuance by 19.1 million shares. The detailed vote tallies and percentages for each resolution are material to investors assessing governance and capital structure decisions.
View raw filing on EDGAR →